Betamethasone

證據等級: L5

預測適應症: 10 個

Betamethasone: From Inflammatory Conditions to Alopecia Areata

One-Sentence Summary

Betamethasone is a potent synthetic glucocorticoid corticosteroid widely used for its anti-inflammatory and immunosuppressive properties across dermatological, rheumatic, and allergic conditions. The TxGNN model predicts it may be effective for Alopecia Areata — an autoimmune condition causing non-scarring hair loss — with 7 clinical trials and 20 publications currently supporting this direction. Evidence ranges from a Cochrane Network Meta-Analysis to multiple RCTs directly testing betamethasone in this indication.

Quick Overview

Item	Content
Original Indication	Broad-spectrum anti-inflammatory and immunosuppressive therapy (no specific SAHPRA-registered indication found in current data)
Predicted New Indication	Alopecia Areata
TxGNN Prediction Score	99.97%
Evidence Level	L2
South Africa Market Status	Not found in SAHPRA database — verify directly with SAHPRA, as this is likely a data gap
Number of SAHPRA Registrations	0 (data gap — betamethasone is on the WHO Essential Medicines List and widely available globally)
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Alopecia areata (AA) is an autoimmune disease driven by CD8⁺ NKG2D⁺ T cells that disrupt the normal “immune privilege” of hair follicles — the biological shield that usually protects them from immune attack. Once this protection collapses, T cells infiltrate the follicle and trigger sustained inflammation, leading to non-scarring hair loss. The key cytokines driving this process include IL-2, IFN-γ, and TNF-α.

Betamethasone acts directly on this pathological cascade. As a high-potency synthetic glucocorticoid, it binds to the glucocorticoid receptor (GR), suppressing the production of the same pro-inflammatory cytokines that underpin AA. It also down-regulates T-cell infiltration into the follicle and reduces MHC class I expression on follicle cells, effectively restoring some degree of immune tolerance. This mechanistic alignment between betamethasone’s pharmacology and AA’s core pathology is direct and biologically well-supported.

Importantly, betamethasone is already applied to AA through three distinct routes in clinical practice — topical application, intralesional injection, and oral mini-pulse therapy — each with dedicated clinical trial evidence. This multi-route real-world utilisation further validates the TxGNN prediction and provides a practical implementation framework for South African prescribers.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06786689	Phase 2	Completed	60	Direct RCT comparing weekly Azathioprine pulse vs Betamethasone Oral Mini-Pulse (BOMP) in moderate-to-severe AA; betamethasone was a primary intervention arm and not merely a comparator
NCT05803070	N/A	Unknown	59	Head-to-head comparison of topical cetirizine 1% vs topical betamethasone valerate 0.1% in localised AA; directly evaluates betamethasone as the target intervention
NCT06087796	Phase 1	Unknown	60	Topical pentoxifylline 2% gel and metformin 10% gel vs topical betamethasone valerate 0.1% cream in patchy AA; betamethasone serves as the established standard comparator
NCT02350023	Phase 4	Completed	50	Topical latanoprost vs topical corticosteroid (including betamethasone) in localised AA; corticosteroids are the standard-of-care reference arm
NCT03535233	Phase 4	Completed	40	Combined topical minoxidil 5% plus potent topical corticosteroid vs intralesional triamcinolone in AA (n=40); evaluates optimal delivery route for corticosteroid therapy
NCT01111981	Phase 4	Unknown	30	Clobetasol propionate 0.05% foam in Central Centrifugal Cicatricial Alopecia; related corticosteroid in a different alopecia subtype — indirect class-level evidence only
NCT04207931	Phase 4	Recruiting	250	Multicenter prospective study examining treatment outcomes across therapies in Central Centrifugal Cicatricial Alopecia; indirect relevance to betamethasone in AA

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37870096	2023	Network Meta-Analysis	Cochrane Database of Systematic Reviews	Comprehensive NMA evaluating all major treatments for AA including immunosuppressants and hair growth stimulants; represents the highest available evidence tier for treatment hierarchy in AA
34400956	2021	RCT	Iranian Journal of Pharmaceutical Research	Double-blind placebo-controlled RCT (n=36) comparing oral betamethasone pulse (3 mg/week) vs methotrexate vs combination in severe AA; provides direct evidence for betamethasone efficacy as monotherapy
39393548	2025	RCT	Journal of the American Academy of Dermatology	RCT evaluating microneedle transdermal delivery of compound betamethasone in AA; demonstrates improved drug delivery with significantly reduced procedural pain vs standard intralesional injection
40510104	2025	RCT	Cureus	Non-blinded RCT (n=60) comparing oral cyclosporine (3 mg/kg) vs betamethasone mini-pulse in AA; provides head-to-head evidence for systemic therapy selection
38623137	2024	Comparative RCT	Cureus	Comparative study of topical betamethasone dipropionate vs topical minoxidil in AA patients; directly assesses relative efficacy of betamethasone in the topical route
40519428	2025	Prospective Clinical Study	Cureus	Prospective assessment of oral betamethasone mini-pulses in moderate-to-severe AA; supports intermittent dosing regimen as a viable alternative to continuous systemic corticosteroids
37992355	2023	Systematic Review	Dermatology Practical & Conceptual	Systematic review of corticosteroid pulse therapy across all subtypes of AA; summarises efficacy, relapse rates, side effects, and prognostic factors
36257912	2022	Comparative Clinical Study	Dermatologic Therapy	Multi-arm blinded RCT (n=108 across 6 groups) comparing latanoprost, minoxidil, betamethasone, and their combinations; provides nuanced comparative data across treatment combinations
36114868	2023	Clinical Trial	Archives of Dermatological Research	Evaluates fractional CO₂ laser alone vs combined with betamethasone valerate cream in AA; supports combination strategy and quantifies betamethasone’s additive contribution
32594786	2022	Within-patient RCT	Journal of Dermatological Treatment	Within-patient RCT directly comparing intralesional betamethasone vs triamcinolone acetonide in localised AA; provides the only head-to-head corticosteroid comparison at this route of administration

South Africa Market Information

According to the current Evidence Pack, no SAHPRA registrations for betamethasone were found in the database queried. This is very likely a data gap rather than a true absence, given that betamethasone is:

Included on the WHO Essential Medicines List
A commonly stocked generic corticosteroid available globally in topical, injectable, and oral formulations
Widely referenced in clinical practice guidelines

Recommended action: Confirm current registration status directly on the SAHPRA MCC website or via the South African Medicines Formulary (SAMF). Check whether betamethasone formulations are included in the National Essential Medicines List (NEML) — particularly topical betamethasone valerate or dipropionate, which are commonly available in public health facilities.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for full safety information. Report adverse drug reactions to SAHPRA.

Practical guidance for prescribers: Betamethasone is a high-potency glucocorticoid. As a class, prescribers should be aware of standard corticosteroid risks including hypothalamic-pituitary-adrenal (HPA) axis suppression with prolonged or high-dose use, skin atrophy and telangiectasia with extended topical application, immunosuppression, and systemic effects in vulnerable populations (children, elderly, patients with diabetes or osteoporosis). For the oral mini-pulse regimen specifically evaluated in AA trials, the once-weekly intermittent schedule is intended to minimise systemic side effects while maintaining therapeutic efficacy. Consult the current SAMF or SAHPRA-approved PI for contraindications, dose adjustments, and drug interaction guidance.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Betamethasone has a mechanistically direct and biologically plausible rationale for use in alopecia areata, supported by a Cochrane Network Meta-Analysis, multiple completed RCTs (including one Phase 2 RCT directly comparing betamethasone to an active comparator), and an established multi-route clinical evidence base — collectively placing this at Evidence Level L2 with a clear pathway for structured implementation.

To proceed, the following is needed:

Confirm SAHPRA registration: Verify current registration of specific betamethasone formulations (topical valerate/dipropionate, injectable, oral) with SAHPRA and confirm NEML inclusion status
Obtain approved PI: Retrieve SAHPRA-approved Professional Information documents for formal safety, contraindication, and drug interaction review before clinical implementation
Define the treatment protocol: Select the most appropriate route for the target patient population (topical for localised AA; oral mini-pulse for moderate-to-severe disease) and establish standardised dosing and monitoring intervals
Safety monitoring plan: Develop monitoring protocols for HPA axis function, skin atrophy (topical route), and glycaemic control, particularly for extended therapy
Pharmacovigilance alignment: Register anticipated use cases with the South African pharmacovigilance system and establish a mechanism for reporting adverse drug reactions to SAHPRA as real-world evidence accumulates in the local population

Disclaimer: This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application. YMYL content — consult a qualified healthcare professional before making any prescribing decisions.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.